Anavex Life Sciences Corp (AVXL)

[McMagyar]

Elsevier had an article about 3 different types of AD patients and their separate subtypes. I could not get article to come up again, but with my limited knowledge, the gist of their point is they identified 3 different models of patients that breakdown into Alzheimers and the 3 Models did so with different speed....
So..IF the beginning and middle of AD has different individual causations than it makes sense that there is not going to be ONE DRUG or treatment for EVERYONE..Which means each successful drug is looking to treat a TYPE..
so..SAFETY is the VALUE at this Point.
PK is the VALUE at this point..
The other POSIITVE Responses from Patients and Caregivers.
THe Dramatic Response of SOME PATIENTS may indicate THOSE are
the TYPE for which A2-73 is highly effective.
This was the first article I had seen that divided AD Patients into
subtypes this way and showed speed of deterioration based upon said subtypes.

"Malignant Progression in Parietal-Dominant Atrophy Subtype of Alzheimer’s Disease Occurs Independent of Onset Age

Published online: August 11, 2016

Han Kyu Na, Dae Ryong Kang, Sungsoo Kim, Sang Won Seo, Kenneth M. Heilman, Young Noh, Duk L. Na

Neurobiology of Aging"